A study published in PLOS Pathogens has stated that a large number of people have the potential to produce neutralizing antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in severe cases of COVID-19.

The study also supports the use of combination antibody therapy for the prevention and treatment of COVID-19. Michael Mor of Tel Aviv University, and colleagues made use of molecular and bioinformatics techniques and compared B-cell responses among 8 patients with severe COVID-19 and 10 patients with mild symptoms, 1.5 months following infection. Patients who were very ill had higher concentrations of RBD-specific antibodies as well as raised B-cell expansion. Twenty two antibodies were cloned from two patients. Of these, 6 were found to have potent neutralization against SARS-CoV-2. It appears that most people can produce neutralizing antibodies against SARS-CoV-2 in severe cases of the disease… (ET Healthworld, February 12, 2021)